Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

Inspira Technologies Oxy B.H.N. Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REVENUES RELATING TO THE BINDING PURCHASE ORDERS EXPECTED TO BE RECEIVED AND RECOGNIZED IN 2026 REVENUES RELATING TO THE BINDING PURCHASE ORDERS EXPECTED TO BE RECEIVED AND RECOGNIZED IN 2026

INSPIRA TECHNOLOGIES REAFFIRMS $49.5 MILLION IN BINDING PURCHASE ORDERS AND ALIGNS EXECUTION WITH 2026 REGULATORY AND DEPLOYMENT MILESTONES

RA'ANANA, ISRAEL, DEC. 15, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN, IINNW) ("INSPIRA,"INSPIRATECHNOLOGIES, OR THE "COMPANY"), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT WITH YA II PN, LTD. (YA) FOR A REGISTERED DIRECT OFFERING OF ITS ORDINARY SHARES, AND HAS ALSO ENTERED INTO A STANDBY EQUITY PURCHASE AGREEMENT (SEPA) WITH YA PROVIDING ADDITIONAL EQUITY FINANCING FLEXIBILITY.

INSPIRA ANNOUNCES $1.8 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET AND ADDITIONAL EQUITY FINANCING AGREEMENT TO SUPPORT ONGOING COMMERCIAL EXECUTION

RA'ANANA, ISRAEL, DEC. 03, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) (INSPIRA, INSPIRA TECHNOLOGIES, OR THE COMPANY), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED A STRATEGIC EXPANSION OF ITS CORE BLOOD LABORATORY CAPABILITIES, MARKING A SUBSTANTIAL STEP IN THE COMPANY'S EVOLUTION INTO A BROADER CUTTING EDGE TECHNOLOGIES, POSITIONING IT FOR ACCELERATED FUTURE GROWTH.

INSPIRA TECHNOLOGIES ANNOUNCES STRATEGIC LEAP IN LAB CAPABILITIES  ACCELERATING NEXT-GENERATION DIAGNOSTICS AND BLOOD TECHNOLOGY

RA'ANANA, ISRAEL, NOV. 13, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," INSPIRA TECHNOLOGIES, OR THE COMPANY), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED THE COMPLETION OF THE CLINICAL STUDY FOR ITS HYLA, NON-INVASIVE BLOOD SENSOR, TOWARD REGULATORY SUBMISSION AND FUTURE COMMERCIALIZATION.

INSPIRA COMPLETES CLINICAL STUDY FOR HYLA BLOOD SENSOR - AHEAD OF REGULATORY SUBMISSION

RA'ANANA, ISRAEL, NOV. 06, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," "INSPIRA TECHNOLOGIES," OR THE "COMPANY"), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED THAT IT HAS COMPLETED THE REGULATORY SUBMISSION OF ITS FDA-CLEARED INSPIRA ART100 SYSTEM (ART100) TO THE UNITED ARAB EMIRATES MINISTRY OF HEALTH AND PREVENTION (MOHAP). FINAL APPROVAL IS EXPECTED WITHIN DAYS, MARKING A DECISIVE STEP TOWARD COMMERCIAL ENTRY INTO THE GULF REGION.

INSPIRA TECHNOLOGIES NEARS FINAL REGULATORY CLEARANCE FOR THE ART100 IN THE UAE, ACCELERATING GULF REGION EXPANSION

RA'ANANA, ISRAEL, OCT. 22, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," INSPIRA TECHNOLOGIES, OR THE "COMPANY"), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED A STRATEGIC COLLABORATION WITH BITES LEARNING LTD. (BITES), A LEADER IN AI-BASED DIGITAL TRAINING AND PERFORMANCE ENABLEMENT SOLUTIONS.

INSPIRA AND BITES FORM STRATEGIC ALLIANCE TO EMBED AI AS A CORE STANDARD ACROSS INSPIRA'S GLOBAL ECOSYSTEM

RA'ANANA, ISRAEL, OCT. 21, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," INSPIRA TECHNOLOGIES, OR THE COMPANY), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED TWO KEY LEADERSHIP APPOINTMENTS THAT REINFORCE ITS GLOBAL COMMERCIALIZATION AND GOVERNANCE  THE APPOINTMENT OF MR. MIKE HERSHKOVITZ AS VICE PRESIDENT OF GLOBAL SALES OF THE COMPANY AND THE APPOINTMENT OF MS. SIVAN MATZA AS A MEMBER OF THE BOARD OF DIRECTORS OF THE COMPANY (THE BOARD). THE BOARD APPOINTED MS. MATZA TO SERVE AS AN INDEPENDENT DIRECTOR OF THE COMPANY UNTIL THE NEXT ANNUAL GENERAL MEETING OF THE COMPANY'S SHAREHOLDERS. MS. MATZA WILL ALSO SERVE AS A MEMBER OF THE BOARD'S COMPENSATION COMMITTEE, AUDIT COMMITTEE AND FINANCIAL STATEMENT EXAMINATION COMMITTEE. MS. MATZA WILL SUCCEED MS. LIMOR ROSEN, WHO IS STEPPING DOWN FROM THE BOARD.

INSPIRA APPOINTS FORMER JOHNSON & JOHNSON EXECUTIVE AS VP OF GLOBAL SALES AND NEW BOARD MEMBER FROM A LEADING INTERNATIONAL INVESTMENT FIRM

INSPIRA DELIVERED MAJOR MILESTONES THROUGHOUT AND FOLLOWING THE SIX MONTHS ENDED JUNE 30, 2025, INCLUDING THE RECEIPT OF $49.5 MILLION IN BINDING PURCHASE ORDERS, CLINICAL VALIDATION IN LEADING HOSPITALS, 97.35% ACCURACY FOR ITS HYLA BLOOD SENSOR, AND STRATEGIC PATENT PROTECTION, UNDERSCORING ACCELERATING COMMERCIAL MOMENTUM. INSPIRA DELIVERED MAJOR MILESTONES THROUGHOUT AND FOLLOWING THE SIX MONTHS ENDED JUNE 30, 2025, INCLUDING THE RECEIPT OF $49.5 MILLION IN BINDING PURCHASE ORDERS, CLINICAL VALIDATION IN LEADING HOSPITALS, 97.35% ACCURACY FOR ITS HYLA BLOOD SENSOR, AND STRATEGIC PATENT PROTECTION, UNDERSCORING ACCELERATING COMMERCIAL MOMENTUM.

INSPIRA TECHNOLOGIES REPORTS FIRST HALF 2025 FINANCIAL RESULTS AND ISSUES BUSINESS UPDATE

RA'ANANA, ISRAEL, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," INSPIRA TECHNOLOGIES, OR THE "COMPANY"), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED PIVOTAL RESULTS FOR ITS HYLA BLOOD SENSOR, ACHIEVING 97.35% ACCURACY IN ITS LATEST PERFORMANCE TESTING PHASE THAT WILL SUPPORT ITS UPCOMING U.S. FOOD AND DRUG ADMINISTRATION (FDA) SUBMISSION. THESE RESULTS REPRESENT A SIGNIFICANT ADVANCEMENT FROM THE INITIAL DATA OBTAINED IN A CLINICAL STUDY, AS ANNOUNCED ON MARCH 4, 2025.

INSPIRA ANNOUNCES 97.3% ACCURACY RESULTS FOR HYLA BLOOD SENSOR, ADVANCING TOWARD FDA SUBMISSION FOR CLEARANCE

RA'ANANA, ISRAEL, AUG. 22, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) ("INSPIRA," INSPIRA TECHNOLOGIES, OR THE "COMPANY"), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, HAS RECEIVED U.S. PATENT APPROVAL FOR LOW FLOW RATES EXTRACORPOREAL OXYGENATION SYSTEM AND METHODS OF USE. THIS PATENT REPRESENTS THE CORE TECHNOLOGY OF THE ART500 DEVICE, A KEY ASSET IN THE COMPANY'S STRATEGY TO PENETRATE THE $20 BILLION ESTIMATED MARKET FOR ADVANCED RESPIRATORY SUPPORT. THIS INNOVATION HAS 16 CLAIMS FOUND TO BE NOVEL.

INSPIRA RECEIVES U.S. PATENT APPROVAL FOR THE ART500 CORE TECHNOLOGY, KEY PATENT POSITIONS THE COMPANY TO DOMINATE $20 BILLION ESTIMATED MARKET

RA'ANANA, ISRAEL, AUG. 07, 2025 (GLOBE NEWSWIRE) -- INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (NASDAQ: IINN) (INSPIRA, INSPIRA TECHNOLOGIES, OR THE COMPANY), A PIONEER IN INNOVATIVE LIFE-SUPPORT AND DIAGNOSTIC TECHNOLOGIES, TODAY ANNOUNCED THAT IT HAS FILED A SHELF REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-289324) WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION ON AUGUST 6, 2025, AS PART OF A ROUTINE SHELF RENEWAL PROCESS CONDUCTED EVERY THREE YEARS. THIS UPDATED FILING REPLACES THE COMPANY'S PREVIOUS SHELF REGISTRATION STATEMENT, WHICH IS SET TO EXPIRE ON AUGUST 18, 2025.

Inspira Technologies Oxy B.H.N. Ltd.

IINN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Inspira Technologies Oxy B.H.N. Ltd.

IINN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IINN